Search

Your search keyword '"Wanten G."' showing total 318 results
Start Over Author "Wanten G."
318 results on '"Wanten G."'

2. Avoiding the use of long-term parenteral support in patients without intestinal failure: A position paper from the European Society of Clinical Nutrition & Metabolism, the European Society of Neurogastroenterology and Motility and the Rome Foundation for Disorders of Gut–Brain Interaction

Author

Lal, S., Paine, P., Tack, J., Aziz, Q., Barazzoni, R., Cuerda, C., Jeppesen, P., Joly, F., Lamprecht, G., Mundi, M., Schneider, S., Szczepanek, K., Van Gossum, A., Wanten, G., Vanuytsel, T., and Pironi, L.

Published
2024
Full Text
View/download PDF

6. Glepaglutide efficacy and safety in short bowel syndrome patients without or with colon-in-continuity: Results of ease sbs 1 phase 3 trial

Author

Pape, U.F., primary, Vanuytsel, T., additional, Subramanian, S., additional, Joly, F., additional, Wanten, G., additional, Lamprecht, G., additional, Kunecki, M., additional, Rahman, F., additional, Nielsen, T.S., additional, Graff, L.B., additional, Berner-Hansen, M., additional, Mercer, D.F., additional, and Jeppesen, P.B., additional

Published
2023
Full Text
View/download PDF

17. Characteristics of adult patients with chronic intestinal failure due to short bowel syndrome: An international multicenter survey.

Author

Pironi, L, Steiger, E, Joly, F, Jeppesen, PB, Wanten, G, Sasdelli, AS, Chambrier, C, Aimasso, U, Mundi, MS, Szczepanek, K, Jukes, A, Theilla, M, Kunecki, M, Daniels, J, Serlie, M, Poullenot, F, Cooper, SC, Rasmussen, HH, Compher, C, Seguy, D, Crivelli, A, Santarpia, L, Guglielmi, FW, Kozjek, NR, Schneider, SM, Ellegard, L, Thibault, R, Matras, P, Matysiak, K, Van Gossum, A, Forbes, A, Wyer, N, Taus, M, Virgili, NM, O'Callaghan, M, Chapman, B, Osland, E, Cuerda, C, Udvarhelyi, G, Jones, L, Won Lee, AD, Masconale, L, Orlandoni, P, Spaggiari, C, Díez, MB, Doitchinova-Simeonova, M, Serralde-Zúñiga, AE, Olveira, G, Krznaric, Z, Czako, L, Kekstas, G, Sanz-Paris, A, Jáuregui, MEP, Murillo, AZ, Schafer, E, Arends, J, Suárez-Llanos, JP, Youssef, NN, Brillanti, G, Nardi, E, Lal, S, Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN, European Society for Clinical Nutrition and Metabolism, Pironi, L, Steiger, E, Joly, F, Jeppesen, PB, Wanten, G, Sasdelli, AS, Chambrier, C, Aimasso, U, Mundi, MS, Szczepanek, K, Jukes, A, Theilla, M, Kunecki, M, Daniels, J, Serlie, M, Poullenot, F, Cooper, SC, Rasmussen, HH, Compher, C, Seguy, D, Crivelli, A, Santarpia, L, Guglielmi, FW, Kozjek, NR, Schneider, SM, Ellegard, L, Thibault, R, Matras, P, Matysiak, K, Van Gossum, A, Forbes, A, Wyer, N, Taus, M, Virgili, NM, O'Callaghan, M, Chapman, B, Osland, E, Cuerda, C, Udvarhelyi, G, Jones, L, Won Lee, AD, Masconale, L, Orlandoni, P, Spaggiari, C, Díez, MB, Doitchinova-Simeonova, M, Serralde-Zúñiga, AE, Olveira, G, Krznaric, Z, Czako, L, Kekstas, G, Sanz-Paris, A, Jáuregui, MEP, Murillo, AZ, Schafer, E, Arends, J, Suárez-Llanos, JP, Youssef, NN, Brillanti, G, Nardi, E, Lal, S, Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN, and European Society for Clinical Nutrition and Metabolism

Abstract

BACKGROUND AND AIMS: The case-mix of patients with intestinal failure due to short bowel syndrome (SBS-IF) can differ among centres and may also be affected by the timeframe of data collection. Therefore, the ESPEN international multicenter cross-sectional survey was analyzed to compare the characteristics of SBS-IF cohorts collected within the same timeframe in different countries. METHODS: The study included 1880 adult SBS-IF patients collected in 2015 by 65 centres from 22 countries. The demographic, nutritional, SBS type (end jejunostomy, SBS-J; jejuno-colic anastomosis, SBS-JC; jejunoileal anastomosis with an intact colon and ileocecal valve, SBS-JIC), underlying disease and intravenous supplementation (IVS) characteristics were analyzed. IVS was classified as fluid and electrolyte alone (FE) or parenteral nutrition admixture (PN). The mean daily IVS volume, calculated on a weekly basis, was categorized as <1, 1-2, 2-3 and >3 L/day. RESULTS: In the entire group: 60.7% were females and SBS-J comprised 60% of cases, while mesenteric ischaemia (MI) and Crohn' disease (CD) were the main underlying diseases. IVS dependency was longer than 3 years in around 50% of cases; IVS was infused ≥5 days/week in 75% and FE in 10% of cases. Within the SBS-IF cohort: CD was twice and thrice more frequent in SBS-J than SBS-JC and SBS-JIC, respectively, while MI was more frequent in SBS-JC and SBS-JIC. Within countries: SBS-J represented 75% or more of patients in UK and Denmark and 50-60% in the other countries, except Poland where SBS-JC prevailed. CD was the main underlying disease in UK, USA, Denmark and The Netherlands, while MI prevailed in France, Italy and Poland. CONCLUSIONS: SBS-IF type is primarily determined by the underlying disease, with significant variation between countries. These novel data will be useful for planning and managing both clinical activity and research studies on SBS.

Published
2021

25. The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine

Author

Broekman, M M T J, Wong, D R, Wanten, G J A, Roelofs, H M, van Marrewijk, C J, Klungel, O H, Verbeek, A L M, Hooymans, P M, Guchelaar, H-J, Scheffer, H, Derijks, L J J, Coenen, M J H, de Jong, D J, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Abstract

The conversion of azathioprine (AZA) to mercaptopurine (MP) is mediated by glutathione transferase Mu1 (GSTM1), alpha1 (GSTA1) and alpha2 (GSTA2). We designed a case-control study with data from the TOPIC trial to explore the effects of genetic variation on steady state 6-methylmercaptopurine ribonucleotide (6-MMPR) and 6-thioguanine nucleotide (6-TGN) metabolite levels. We included 199 patients with inflammatory bowel disease (126 on AZA and 73 on MP). GSTM1-null genotype carriers on AZA had two-fold lower 6-MMPR levels than AZA users carrying one or two copies of GSTM1 (2239 (1006-4587) versus 4371 (1897-7369) pmol/8 × 10(8) RBCs; P

Published
2018

28. The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Broekman, M M T J, Wong, D R, Wanten, G J A, Roelofs, H M, van Marrewijk, C J, Klungel, O H, Verbeek, A L M, Hooymans, P M, Guchelaar, H-J, Scheffer, H, Derijks, L J J, Coenen, M J H, de Jong, D J, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Broekman, M M T J, Wong, D R, Wanten, G J A, Roelofs, H M, van Marrewijk, C J, Klungel, O H, Verbeek, A L M, Hooymans, P M, Guchelaar, H-J, Scheffer, H, Derijks, L J J, Coenen, M J H, and de Jong, D J

Published
2018

29. Randomised clinical trial:2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition

Author

Wouters, Y, Theilla, M, Singer, P, Tribler, S, Jeppesen, P B, Pironi, L, Vinter-Jensen, L, Rasmussen, H H, Rahman, F, Wanten, G J A, Wouters, Y, Theilla, M, Singer, P, Tribler, S, Jeppesen, P B, Pironi, L, Vinter-Jensen, L, Rasmussen, H H, Rahman, F, and Wanten, G J A

Abstract

BACKGROUND: The catheter lock solutions 2% taurolidine and 0.9% saline are both used to prevent catheter-related bloodstream infections (CRBSIs) in home parenteral nutrition patients.AIMS: To compare the effectiveness and safety of taurolidine and saline.METHODS: This multicentre double-blinded trial randomly assigned home parenteral nutrition patients to use either 2% taurolidine or 0.9% saline for 1 year. Patients were stratified in a new catheter group and a pre-existing catheter group. Primary outcome was the rate of CRBSIs/1000 catheter days in the new catheter group and pre-existing catheter group, separately.RESULTS: We randomised 105 patients, of which 102 were analysed as modified intention-to-treat population. In the new catheter group, rates of CRBSIs/1000 catheter days were 0.29 and 1.49 in the taurolidine and saline arm respectively (relative risk, 0.20; 95% CI, 0.04-0.71; P = 0.009). In the pre-existing catheter group, rates of CRBSIs/1000 catheter days were 0.39 and 1.32 in the taurolidine and saline arm respectively (relative risk, 0.30; 95% CI, 0.03-1.82; P = 0.25). Excluding one outlier patient in the taurolidine arm, mean costs per patient were $1865 for taurolidine and $4454 for saline (P = 0.03). Drug-related adverse events were rare and generally mild.CONCLUSIONS: In the new catheter group, taurolidine showed a clear decrease in CRBSI rate. In the pre-existing catheter group, no superiority of taurolidine could be demonstrated, most likely due to underpowering. Overall, taurolidine reduced the risk for CRBSIs by more than four times. Given its favourable safety and cost profile, taurolidine locking should be considered as an additional strategy to prevent CRBSIs.TRIAL REGISTRATION: Clinicaltrials.gov, identifier: NCT01826526.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results